secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-05-19T23:59:59+00:00
Accession:  0001193125-23-148827
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha TSHA-102 data: safe in wild-type mice, extends survival >4x in Rett model
--------------------------------------------------------------------------------

- New wild-type mouse data: TSHA-102 showed no toxicity or survival reduction over 36 weeks, no impact on neurobehavioral function.
- In Mecp2–/Y knockout mice, TSHA-102 led to 47% survival at 36 weeks vs median 8.1 weeks in vehicle group (>4-fold extension, p<0.0001).
- TSHA-102 significantly delayed onset of severe Rett phenotypes: severe clasping from ~7 to 21 weeks, abnormal gait from ~8 to 20 weeks.
- Dosing of first adult patient in Phase 1/2 REVEAL trial expected Q2 2023; initial safety data anticipated Q2 2023.
- TSHA-102 uses miRARE technology to regulate MeCP2 expression, addressing risks of both under- and overexpression in mosaic X-chromosome silencing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523148827/0001193125-23-148827-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523148827/d511724d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-148827

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer